These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 1574257)

  • 1. Intersite variation of estrogen receptors in human breast cancers and response to endocrine therapy. Which section of a large tumor is the best for estrogen receptor assay?
    Iino Y; Sugamata N; Maemura M; Takeo T; Owada S; Yokoe T; Ishikita T; Horiuchi R; Morishita Y
    Oncology; 1992; 49(2):89-92. PubMed ID: 1574257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptors and breast cancer: prognostic and therapeutic implications.
    Gapinski PV; Donegan WL
    Surgery; 1980 Sep; 88(3):386-93. PubMed ID: 7414516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
    Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
    J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Histochemical and biochemical assays of estrogen receptors in breast cancer and significance of endocrine therapy].
    Tominaga T
    Gan No Rinsho; 1983 May; 29(6):628-31. PubMed ID: 6308307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormone receptors: clinical significance and problems in the treatment of breast cancer].
    Izuo M; Iino Y
    Gan No Rinsho; 1983 May; 29(6):637-43. PubMed ID: 6876433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy.
    Toi M; Nakamura T; Wada T; Yamamoto A; Toge T; Niimoto M; Hattori T
    Jpn J Surg; 1989 Nov; 19(6):768-72. PubMed ID: 2514309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. St. Gallen endocrine response classes predict recurrence rates over time.
    Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
    Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of endocrine therapy on the proliferation of estrogen (ER) positive cells and ER negative cells of human breast cancer (MCF-7)].
    Noguchi M; Tajiri K; Taniya T; Kumaki T; Miyazaki I
    Nihon Geka Gakkai Zasshi; 1989 May; 90(5):780-5. PubMed ID: 2529423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy.
    McClelland RA; Berger U; Miller LS; Powles TJ; Coombes RC
    J Clin Oncol; 1986 Aug; 4(8):1171-6. PubMed ID: 2426418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognosis, stage and oestrogen receptor status of contralateral breast cancer in relation to characteristics of the first tumour, prior endocrine treatment and radiotherapy.
    Alkner S; Ehinger A; Bendahl PO; Rydén L; Fernö M
    Eur J Cancer; 2015 Nov; 51(16):2304-13. PubMed ID: 26243193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple estrogen receptor assays in human breast cancer.
    Hull DF; Clark GM; Osborne CK; Chamness GC; Knight WA; McGuire WL
    Cancer Res; 1983 Jan; 43(1):413-6. PubMed ID: 6847780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: correlation with clinical endocrine response.
    Andersen J; Poulsen HS
    J Steroid Biochem; 1988; 30(1-6):337-9. PubMed ID: 3386262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differing predictive values of oestrogen receptor assays for large breast cancers.
    Gaskell DJ; Hawkins RA; Tesdale AL; Sangster K; Chetty U; Forrest AP
    Postgrad Med J; 1992 Nov; 68(805):900-3. PubMed ID: 1494511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunocytochemical determination of the estrogen-regulated protein Mr 24,000 in primary breast cancer and response to endocrine therapy.
    Andersen J; Skovbon H; Poulsen HS
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):641-3. PubMed ID: 2714341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid receptors in breast cancer.
    Desombre ER
    Monogr Pathol; 1984; (25):149-74. PubMed ID: 6377047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.